Rontalizumab, a novel therapeutic agent , demonstrates promising utility in targeting specific inflammatory pathways. This advanced treatment shows the chance to inhibit interleukin-6 receptor (IL-6R), a key https://www.targetmol.com/compound/rontalizumab